title: Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
abstract: BACKGROUND
  The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients.
  
  
  METHODS
  We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months.
  
  
  CONCLUSIONS
  These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.
authors.affiliation: Division of Hematology, Phoenix Children's Hospital, Phoenix, AZ 85016, USA. phingorani@phoenixchildrens.com
authors.forename: Pooja
authors.initials: P
authors.lastname: Hingorani
authors.forename: Francis
authors.initials: F
authors.lastname: Eshun
authors.forename: Andrea
authors.initials: A
authors.lastname: White-Collins
authors.forename: Masayo
authors.initials: M
authors.lastname: Watanabe
mesh_terms: D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D012509:Sarcoma / Q000098:blood supply / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis; D000093542:Gemcitabine
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D000077143:Docetaxel; D000068258:Bevacizumab; D000093542:Gemcitabine